- The trend backdrop is active with a 6-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
BAYN
GER
Week ended 07 Aug 2026
Weekly Investor Report
Bayer Aktiengesellschaft · Healthcare · Drug Manufacturers - General
Latest close
49.81 EUR
3.7%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 18.8% above the Trend Line and sits at 85.6% of its 52-week range. The latest completed week returned 3.7%, after a -0.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 53/100.
Setup score
64
out of 100
Latest Close
49.81 EUR
7 Aug 2026
1W Return
3.7%
latest completed week
4W Return
-0.6%
short-term follow-through
12W Return
32.1%
quarterly tape
Trend Breadth
90.4%
47 of 52 weeks active
Volume Ratio
1.5x
vs 13-week average
- 2 reversal markers appear in the recent smart-money tape.
- Recent volatility is running well above the one-year baseline.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
3.7%
Latest completed week; four-week move -0.6%.
Indicator stack
70/69
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
53/100
29 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 18.8% above the Trend Line and sits at 85.6% of its 52-week range. The latest completed week returned 3.7%, after a -0.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.5x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.4812-week average 0.37
12-week confirmation
Trend active7/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.48Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -0.6% over four weeks, 32.1% over 12 weeks, and 94.3% over one year. The current trend has remained active for 6 consecutive weeks.
Performance by holding period
Active trend streak6 weeks
Active weeks in one year47
Trend breadth90.4%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.78Latest activity-pressure read.
Pressure change62.1%Four-week change in activity pressure.
Leadership25.08Latest relative-leadership reading.
RS change-32.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 85%
Model confidence 79%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength90/100Blend of value, momentum, and quality. Underlying universe rank 11; rank 1 is best.
Value64/100Relative valuation strength. Underlying universe rank 37; rank 1 is best.
Quality69/100Profitability and accounting quality. Underlying universe rank 32; rank 1 is best.
Momentum92/100Medium-term price momentum. Underlying universe rank 9; rank 1 is best.
Growth29/100Revenue and earnings growth. Underlying universe rank 72; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework82/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 1.1x Market value relative to trailing revenue.
- EV / EBITDA
- 27.1x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 3.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 59.3% Gross profit retained from each unit of revenue.
- Operating margin
- 16.2% Operating profit retained from revenue.
- Free-cash-flow margin
- 5.8% Free cash flow generated from revenue.
- Return on invested capital
- 9.2% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -2.2% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -25.0% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.2% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.2% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 10.4x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment53/100
Weighted news tone is neutral across 29 relevant articles.
6 positive · 21 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-7.6%Distance below the 52-week high.
13-week volatility8.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+24.2%Week of 26 Jun.
Worst week-13.4%Week of 6 Mar.
Latest week+3.7%Week of 7 Aug.
Shape of recent returns
Strong gains5
Modest gains8
Flat weeks0
Modest losses7
Sharp losses6
Recent vol8.0%13-week weekly-return volatility.
Base vol5.9%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew5.3% / -3.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank44 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Drug Manufacturers - General
4-week rank8 / 12
Group average2.5%
Trend breadth58.3%
Trend58.3%active weekly trend signals
MD83.3%positive activity pressure
RS66.7%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape63/100
Trend, activity pressure, participation, and risk combine to a 63/100 tape read.
Indicator analysis55/100Latest 12-week confirmation: trend 7/12, activity pressure 5/12, relative leadership 12/12.
Activity pressure 0.48; 2 reversal markers Factors78/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 42; Small Cap Core rank 70 SVQF82/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 70.0 of 375 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment53/100Weighted news tone is neutral across 29 relevant articles.
Bayer Stock Jumps 3.7% as Seed Profit Tops Forecasts Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 49.81 EUR | 3.7% | 41.94 EUR | 31.28 EUR | 0.78 | 25.08 | 13.5M | On |
| 31 Jul 2026 | 48.05 EUR | 4.3% | 41.57 EUR | 31.30 EUR | 0.86 | 25.23 | 9.3M | On |
| 24 Jul 2026 | 46.06 EUR | -5.0% | 41.24 EUR | 31.32 EUR | 0.89 | 23.65 | 8.7M | On |
| 17 Jul 2026 | 48.46 EUR | -3.3% | 40.89 EUR | 31.35 EUR | 0.87 | 32.59 | 10.0M | On |
| 10 Jul 2026 | 50.12 EUR | -6.1% | 40.47 EUR | 31.37 EUR | 0.48 | 37.30 | 14.3M | On |
| 3 Jul 2026 | 53.36 EUR | 13.5% | 40.01 EUR | 31.37 EUR | -0.14 | 43.80 | 4.2M | On |
| 26 Jun 2026 | 47.00 EUR | 24.2% | 39.34 EUR | 31.34 EUR | -0.76 | 34.09 | 7.7M | Off |
| 19 Jun 2026 | 37.84 EUR | 4.6% | 38.79 EUR | 31.36 EUR | -1.16 | 7.74 | 8.9M | Off |
| 12 Jun 2026 | 36.19 EUR | 0.1% | 38.44 EUR | 31.43 EUR | -1.25 | 5.05 | 1.8M | Off |
| 5 Jun 2026 | 36.16 EUR | -1.0% | 38.18 EUR | 31.53 EUR | -1.20 | 4.88 | 2.2M | Off |
| 29 May 2026 | 36.53 EUR | -5.1% | 37.84 EUR | 31.63 EUR | -1.06 | 5.04 | 15.6M | Off |
| 22 May 2026 | 38.51 EUR | 2.1% | 37.52 EUR | 31.72 EUR | -1.03 | 12.36 | 9.7M | On |
| 15 May 2026 | 37.71 EUR | 2.0% | 37.16 EUR | 31.82 EUR | -0.98 | 15.16 | 13.3M | On |
| 8 May 2026 | 36.98 EUR | -2.8% | 36.79 EUR | 31.93 EUR | -0.89 | 12.10 | 10.7M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.